Trials / Completed
CompletedNCT00316602
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 632 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMVAMUNE | Subjects receiving two subcutaneous vaccinations |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-11-01
- Completion
- 2010-04-01
- First posted
- 2006-04-21
- Last updated
- 2019-01-09
- Results posted
- 2019-01-09
Locations
22 sites across 2 countries: United States, Mexico
Source: ClinicalTrials.gov record NCT00316602. Inclusion in this directory is not an endorsement.